Inhibition of interleukin‐5 mediated eosinophil viability by fluticasone 17‐propionate: comparison with other glucocorticoids
- 1 August 1998
- journal article
- research article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 28 (8), 999-1006
- https://doi.org/10.1046/j.1365-2222.1998.00363.x
Abstract
Inhaled glucocorticoids are commonly employed to treat patients with asthma. Eosinophils are important effector cells in the pathogenesis of asthma, and, in vitro, glucocorticoids modulate eosinophil viability. Using this glucocorticoid inhibition of eosinophil viability, we compared the in vitro potencies of several inhaled glucocorticoids with particular attention to fluticasone 17-propionate. Eosinophils from normal or mildly atopic donors were purified, cultured with cytokines and glucocorticoids, and on day 4, after staining with propidium iodide, analysed by flow cytometry. Eosinophil viability was prolonged by interleukin (IL)-5 in a concentration-dependent manner; in contrast, dexamethasone inhibited the IL-5 effect. Fluticasone 17-propionate, 1.0–1000 nM, also inhibited the IL-5 effect in a concentration-dependent manner; interestingly, at 0.1 nM fluticasone 17-propionate modestly, but significantly, enhanced eosinophil survival. High concentrations of IL-5 and granulocyte-macrophage colony-stimulating factor essentially completely overcame the inhibitory effect of 1000 nM fluticasone 17-propionate on eosinophil survival. In contrast, although interferon-γ-mediated eosinophil viability was inhibited by 1.0–1000 nM fluticasone 17-propionate, this inhibition was not overcome by increased concentrations of interferon-γ. Comparison of the glucocorticoid inhibition of eosinophil viability in the presence of 10 pg/mL IL-5 resulted in these drug IC50 values (in nM): fluticasone 17-propionate, 1.3; budesonide, 8.5; triamcinolone acetonide, 25; flunisolide, 32; dexamethasone, 94; beclomethasone 17-monopropionate, 210; beclomethasone 17,21-dipropionate, 290; and hydrocortisone, >1000. Fluticasone 17-propionate's effect on cytokine-mediated eosinophil viability is similar qualitatively to other glucocorticoid preparations. However, quantitatively, fluticasone 17-propionate has the most potent suppressive effects on IL-5 mediated eosinophil viability among the currently available inhaled glucocorticoids in the United States.Keywords
This publication has 19 references indexed in Scilit:
- Eosinophil granule proteins and bronchial asthmaAllergology International, 1996
- Inhaled Glucocorticoids for AsthmaNew England Journal of Medicine, 1995
- Ammonium chloride exposure inhibits cytokine-mediated eosinophil survivalJournal of Immunological Methods, 1994
- Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy.JCI Insight, 1994
- Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow cytometryBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1992
- An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophilsJournal of Immunological Methods, 1991
- Mast cell growth‐enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9)European Journal of Immunology, 1990
- Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthmaJournal of Allergy and Clinical Immunology, 1987
- Effects of glucocorticoids on eosinophil colony growthJournal of Allergy and Clinical Immunology, 1986
- Criteria of cell killing in vitroJournal of Immunological Methods, 1981